Ironwood Pharmaceuticals | IRWD - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
Ardelyx USD 102.27M 26.35M 2026-03
Astellas Pharma JPY 215.07B 19.63B 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Charles River Laboratories USD 228.9M 69.47M 2026-06
Coherus Biosciences USD 15M 6.26M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
MacroGenics USD 9.71M 1.77M 2026-03
Moderna USD 216M 43M 2026-06
Myriad Genetics USD 122.3M 6.7M 2025-12
Pacira USD 91.81M 7.93M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Takeda JPY 286.51B 5.48B 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12